HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

C-galactosylceramide

an antimalarial; structure in first source

Also Known As:

alpha-C-GalCer

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Franck, Richard W: 5 articles (01/2010 - 12/2003)
2.	Tsuji, Moriya: 5 articles (01/2010 - 12/2003)
3.	Schmieg, John: 2 articles (01/2010 - 12/2003)
4.	Yang, Guangli: 2 articles (01/2010 - 12/2003)
5.	Chen, Guangwu: 2 articles (08/2007 - 07/2006)
6.	Brintnell, William C: 1 article (07/2012)
7.	Cairns, Ewa: 1 article (07/2012)
8.	Haeryfar, S M Mansour: 1 article (07/2012)
9.	Mannik, Lisa A: 1 article (07/2012)
10.	Mazzuca, Delfina M: 1 article (07/2012)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2007 - "NKTMab therapy containing either alpha-galactosylceramide (alpha-GC) or alpha-C-galactosylceramide (alpha-c-GC) at high concentrations induced similar rates of tumor rejection in mice; however, toxicity was observed at the highest doses of alpha-GC (>250 ng/injection), limiting the use of this glycolipid. " 07/25/2006 - "When glycolipid is targeted to dendritic cells in spleen together with antigens in dying cells, such as irradiated tumor cells, alpha-C-GalCer is active as an adjuvant for T cell-mediated immunity at lower doses, just 20 ng per mouse, where it is also able to up-regulate the required CD40L costimulatory molecule on NKT cells. "
2.	Neoplasm Metastasis (Metastasis) 11/01/2009 - "Single doses of alpha-GalCer, alpha-C-GalCer, or OCH were sufficient to prevent liver metastasis and subsequent doses failed to elicit optimal cytokine responses. " 12/01/2003 - "In two disease models requiring Th1-type responses for control, namely malaria and melanoma metastases, alpha-C-GalCer exhibited a 1,000-fold more potent antimalaria activity and a 100-fold more potent antimetastatic activity than alpha-GalCer. "
3.	Malaria 12/01/2003 - "In two disease models requiring Th1-type responses for control, namely malaria and melanoma metastases, alpha-C-GalCer exhibited a 1,000-fold more potent antimalaria activity and a 100-fold more potent antimetastatic activity than alpha-GalCer. " 01/01/2010 - "We have previously shown that the C-glycoside analog of alpha-galactosylceramide (alpha-GalCer), alpha-C-GalCer, displays a superior inhibitory activity against the liver stages of the rodent malaria parasite Plasmodium yoelii than its parental glycolipid, alpha-GalCer. "
4.	Arthritis (Polyarthritis) 08/15/2007 - "Whereas in vivo neutralization of IFN-gamma release induced by either alpha-GalCer or alpha-C-GalCer early during the course of disease resulted in partial improvement of clinical arthritis symptoms, blockade of IFN-gamma release later on resulted in a more rapid onset of arthritis. " 07/01/2012 - "Interestingly, administering the Th1-promoting iNKT cell glycolipid ligand α-C-galactosylceramide into HLA-DR4 transgenic mice increased the incidence of arthritis in these animals and exacerbated their clinical symptoms, strongly suggesting a role for Th1 responses in the pathogenesis of citrulline-induced arthritis. "
5.	Experimental Melanoma 07/25/2006 - "Also, alpha-C-GalCer better mobilizes NKT and natural killer cells to resist B16 melanoma. "

Related Drugs and Biologics

1.	alpha-galactosylceramide
2.	Glycolipids
3.	CD40 Ligand (CD40L)
4.	Cytokines
5.	HLA-DR4 Antigen (HLA DR4 Antigen)
6.	Ligands
7.	Citrulline
8.	Antigens
9.	C-glycoside

Related Therapies and Procedures

1.	Therapeutics